VioQuest Pharmaceuticals, Inc.' VQD-002 Named One of 10 Most Promising Oncology Projects by Windhover Information Inc.

BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VOQP) announced today that the company’s novel Akt inhibitor VQD-002 (triciribine phosphate monohydrate, or TCN-P) has been selected as one of the Top 10 most promising oncology projects in development available for strategic partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

Back to news